Advertisement

Current Bladder Dysfunction Reports

, Volume 9, Issue 3, pp 175–180 | Cite as

Pelvic Organ Prolapse-Associated Cystitis

  • Rizwan Hamid
  • Giovanni Losco
Open Access
Inflammatory/Infectious Bladder Conditions (S Mourad, Section Editor)

Abstract

Pelvic organ prolapse (POP) and urinary tract infection (UTI) are important problems, estimated to affect around 14 and 40 % of women, respectively, at some point in their lives. Positive urine culture in the presence of symptoms is the cornerstone of diagnosis of UTI and should be performed along with ultrasound assessment of postvoid residual (PVR) in all women presenting with POP and UTI. PVR over 30 mL is an independent risk factor for UTI, although no specific association with POP and UTI has been demonstrated. The use of prophylactic antibiotics remains controversial. The major risk factors for postoperative UTI are postoperative catheterisation, prolonged catheterisation, previous recurrent UTI and an increased urethro-anal distance—suggesting that global pelvic floor dysfunction may play a role.

Keywords

Prolapse Pelvic organ prolapse Cystocele Vagina Urinary bladder Rectocele Urinary tract Urinary tract infections Bacteriuria Pyuria Cystitis Urinary incontinence Urinary incontinence, stress Urinary incontinence, urge Surgical mesh Anti-bacterial agents Antibiotic prophylaxis 

Introduction

Pelvic organ prolapse (POP) and urinary tract infection (UTI) are common problems. Urinary tract infection (UTI) will affect around 40 % of women in their lifetime, and a recurrent UTI will affect around 27 % within the following 6 to 12 months. The annual incidence of surgery for POP is up to 50 cases per 10,000 women-years. This is expected to double in the next 30 years [1].

A definition for recurrent UTIs is not universally accepted. Two, three, or four or more [2, 3, 4] UTIs in the preceding 12 months are some of the commonest definitions. There has been no comprehensive study of recurrent UTIs in large groups, across all ages, or for their relationships and associations to a wide range of urodynamic and clinical parameters. In particular, their relationship to POP is not well documented in the literature despite the common occurrence of these two entities in older females and the presence of a possible cause and effect mechanism in some cases.

In the previous literature, the separation of risk factors for recurrent UTI in women has tended to be on the basis of age. Commonly, three groups are identified: young premenopausal women, menopausal women between 50 and 70 years, and elderly women. Most studies to date reflect these patient groups [5].

There are a number of factors associated with young women and recurrent UTI. Most commonly these are sexual intercourse [6, 7], which includes a new sexual partner in the previous 12 months [6]; the use of contraceptives, especially spermicides, diaphragms and oral contraceptives [6, 8, 9]; family history [10]; and urethro-anal distance (UAD) [11]. The increased susceptibility of women with recurrent UTI to vaginal colonisation with certain uropathogens compared to women without recurrent UTI has been the focus of other studies [12]. The prevalence of recurrent UTI in women who are non-secretors of ABO blood group antigens has been found to be up to four times higher than in secretors (uropathogenic Escherichia coli have superior adherence to the uroepithelial cells of non-secreting women, hence an elevated risk of clinical infection in these women) [13].

Postmenopausal women have a different array of common risk factors for recurrent UTI. These are UTI history before menopause, oestrogen deficiency, surgery to the urogenital region, cystocele, elevated postvoid residual (PVR), and previous UTI [14, 15]. Cystocele, with its association with elevated PVR, means a number of women with POP will concomitantly present with recurrent UTIs. This presents a management dilemma. Does the presence of prolapse contribute to UTI? Will management of the prolapse decrease the risk of UTI? Is there an associated risk of postoperative UTI? In this review, we look at the current evidence regarding POP and associated cystitis or UTI.

What Is POP?

POP affects a significant number of women in the UK, with anywhere from 11 to 14 % requiring surgical intervention at some point in their lifetimes [16, 17]. The USA alone performs approximately 200,000 pelvic prolapse surgical procedures per year [18]. Women may present with the sensation of dragging or a lump in their vagina, with sexual dysfunction, or with bladder and/or bowel dysfunction. In a small number of patients, recurrent UTIs may be the single presenting complaint.

Proper pelvic floor anatomy and prevention of POP are reliant upon maintaining the proper anatomical support mechanisms [19••]. The bony pelvis is composed of two hip bones connected posteriorly by the sacrum and anteriorly by the pubic symphysis. The female pelvis is wider than in the male so as to accommodate childbirth; however, this creates a predisposition for pelvic floor weakness. The pelvic diaphragm is composed of the levator ani and coccygeus muscles. It is the fusion of the posterior fibres of the pubococcygeus muscles with the iliococcygeus muscle that forms the levator plate, a structure between the anus and the coccyx that the pelvic organs rest upon. Levator ani weakness may lead to a sagging of the levator plate, which opens the urogenital hiatus and predisposes to POP [19••]. The endopelvic fascia is a dense collection of collagen, elastin, smooth muscle, fibroblasts and vessels that connects the bladder, urethra, vagina and uterus to the pelvic sidewall [20]. It is this endopelvic fascia, surrounding the vagina and connecting laterally to the arcus tendineus fascia, that provides pelvic sidewall attachment as well as support to the vaginal walls [21].

Three levels of connective tissue support have been described for the vagina. Level I support consists of the uterosacral ligament, connecting the cervix and upper vagina. This inserts onto the pelvic sidewall and sacrum. It is at this level that integrity of the vaginal apex is maintained, which is now understood to be critically important in repair. Level II support maintains anterior vaginal functional anatomy. It is composed of the pubocervical fascia along the length of the vagina. Finally, level III support maintains distal function and anatomy. This consists of the perineal membrane, perineal body and the superficial and deep transverse perineal muscles [19••, 21].

Defects at any of these levels, and usually a combination of two or all three of them, result in typical anterior compartment prolapse (cystocele), which may predispose to UTIs. Rarely, a significant posterior compartment prolapse (rectocele) may press anteriorly on the bladder neck and urethra causing obstructive voiding, urgency/frequency and/or elevated postvoid residuals, in turn raising the possibility of recurrent UTI.

The scope of POP repair is beyond this article, but the best practice methods are based on restoring normal vaginal anatomy to maintain adequate vaginal axis, length and function (see Table 1). Multiple surgical approaches have been described, including transvaginal repairs (with and without mesh), sacrospinous fixation, abdominal sacrocolpopexy, laparoscopic sacrocolpopexy and robotic sacrocolpopexy. Regardless of the location of defect, it is becoming evident that of critical importance for a durable and effective repair is the adequate fixation of the vaginal apex. The Surgery for Pelvic Organ Prolapse Committee has described the apex as the “keystone of pelvic organ support” and further emphasises that “the best surgical correction of the anterior and posterior walls may fail unless the apex is adequately supported” [21, 22, 23•].
Table 1

Types of prolapse repair by surgical approach

Surgical approach

Type of repair

Conservative

Ring pessary

Transvaginal approach

Anterior colporrhaphy

Posterior colporrhaphy

Mesh repair

Sacrospinous fixation

Abdominal approach

Open sacrocolpopexy

Laparoscopic sacrocolpopexy

Robotic sacrocolpopexy

What Is Cystitis?

Broadly, UTI or cystitis is defined as an infection of the urinary system and may involve the lower urinary tract or both the lower and upper urinary tracts [24]. It ranges on a spectrum from asymptomatic bacteriuria, to symptomatic UTI, to urinary sepsis requiring hospitalisation (see Table 2) [25, 29••]. Asymptomatic bacteriuria in women is defined as presence of at least 105 CFU/mL of the same uropathogen in two consecutive clean-catch midstream urine samples obtained from patients without any symptoms or signs attributable to urinary infection. Asymptomatic bacteriuria is a state of colonisation, not disease, and does not indicate an infection that requires treatment [26, 27, 28].
Table 2

Types of UTI and their definitions

Condition

Definition

Asymptomatic bacteriuria

Presence of at least 105 CFU/mL of the same uropathogen in two consecutive clean-catch midstream urine samples obtained from patients without any symptoms or signs attributable to urinary infection

Symptomatic UTI

Symptoms and signs of UTI and laboratory tests confirming the diagnosis (bacteriuria of at least 105 CFU/mL and pyuria of at least 10 white blood cells per high-powered field)

Uncomplicated UTI

UTI in a normal urinary tract without prior surgery or instrumentation

Complicated UTI

UTI where there is a functional or structural abnormality, previous urinary instrumentation or surgery, systemic diseases such as renal insufficiency, diabetes or immunodeficiency, or previous renal transplant

Urosepsis

Sepsis due to UTI

Establishing a diagnosis of symptomatic UTI requires a patient to have symptoms and signs of UTI and laboratory tests confirming the diagnosis (bacteriuria of at least 105 CFU/mL and pyuria of at least 10 white blood cells per high-powered field). Uncomplicated symptomatic UTI is present when there is a symptomatic bladder infection manifested by dysuria, worsened urinary frequency or urgency, fever, suprapubic tenderness, costovertebral angle tenderness with no other cause attributable and laboratory tests revealing UTI [29••]. Fever is usually not present in symptomatic UTI that is localised to the bladder. Complicated UTI is defined as having a symptomatic UTI in patients caused by a functional or structural abnormality, having had urinary instrumentation, having systemic diseases such as renal insufficiency, diabetes, or immunodeficiency or having undergone renal transplantation [30, 31, 32, 33]. Pyuria is simply defined as the presence of leukocytes in the urine.

Investigations for UTI

Most patients, but not all, will present with dysuria, frequency, urgency, nocturia and urge incontinence. Malodorous urine and haematuria may be present. Very elderly patients, and patients who are neurologically impaired, may present differently, and a high level of suspicion should be had for UTI. Patients who are reliant on self-catheterisation in order to void may suffer only from lower abdominal pain or systemic malaise in the absence of specific lower urinary tract symptoms. Fever is uncommon in the first instance but in some patients will be the only symptom. However, when superimposed with a high prevalence of chronic genitourinary symptoms, increasing cognitive impairment and a high comorbidity load with advancing age, diagnosis and management of a symptomatic UTI remains a challenge [29••].

Clinical examination, including the formal examination for prolapse, should be performed.

The cornerstone of UTI diagnosis is the presence of a positive urinary culture. For this reason, a urine specimen should always be sent for microscopy, culture and sensitivity. Irritative bladder symptoms, not due to infection, must be ruled out by the presence of a positive urine culture before the patient is considered to have a UTI. Documented positive cultures become important when counselling patients as to whether treatment of their prolapse will have any effect on their symptoms. Imaging should include ultrasound assessment of the bladder and kidneys, including an assessment of postvoid residual.

UTI in Association With POP

Haylen et al. conducted an interesting prospective study of 1,140 women presenting for routine urogynaecological assessment due to symptoms of pelvic floor dysfunction. All patients underwent urodynamic studies [34]. Significant risks for an increased prevalence of recurrent UTI in women were found to be nulliparity and a PVR over 30 mL.

This appears to be the first time that nulliparity and recurrent UTI have been so clearly linked. A mechanism was proposed by the authors whereby parity could in fact protect against recurrent UTIs. As parity increases, number of sexual partners may decrease. Furthermore, new mothers may be less likely to engage in intercourse due to the stresses that a new child brings [5, 6, 7, 8, 9]. The effect of pregnancy and childbirth on relaxing and stretching the birth canal may help in preventing UTIs: if the friction of intercourse has a role in promoting recurrent UTIs, this would have a lesser impact postpartum [34]. It is known that sexual histories are difficult to study in a research context due to the difficulty in obtaining them making this theory difficult to prove.

An elevated PVR is another significant factor associated with recurrent UTIs (over 30 mL). The level of PVR, described by O’Grady and Cattell, at which UTI becomes more frequent, was 30 mL [35]. An upper limit of normal PVR of 30 mL is supported if measured immediately after voiding by an accurate ultrasound method [36, 37]. An ultrasound PVR assessment is therefore recommended for women with recurrent UTI.

Voiding dysfunction is commonly seen with anterior compartment prolapse and is often under-recognised. In the Haylen paper, women with a final diagnosis of voiding dysfunction had an increased chance of recurrent UTI. This diagnosis included an assessment of PVR, flow rate and pressure-flow studies [34]. Up to 39 % of women attending for assessment of the urogenital tract have been found to have a preliminary diagnosis of voiding dysfunction, where slow or incomplete micturition is included as diagnostic criteria [38]. The final diagnosis and the quest for a cause rely upon formal urodynamic assessment.

Interestingly, in the Haylen paper, no specific association with UTI and prolapse was seen. An increasing negative association between recurrent UTI and prolapse of higher grade is difficult to explain. The link between voiding dysfunction and prolapse has been documented [38]. Despite the link between voiding dysfunction and recurrent UTI, there is an inverse relationship between prolapse and recurrent UTI. It is possible that due to the increased risk of recurrent UTI in nulliparous women where the stretching effects of childbirth are not found that this further increases the apparent risk—whereas in parous women with prolapse, the stretching effects have obviously been marked, decreasing the UTI risk as detailed earlier [39].

Postoperative UTI

After surgery for pelvic organ prolapse (POP) or stress urinary incontinence (SUI), UTIs are the most common complication [40, 41]. By the age of 80 years, up to one in nine women will seek surgery for POP and SUI due to their prevalence in women [42, 43]. A major trial where autologous sling was compared to Burch colposuspension for treatment of SUI was known as the SISTEr trial. In the sling group, 48 % of women suffered a UTI compared to 32 % in the Burch group during the first 24 months of follow-up [40]. In a further study in the Medicare population, where 1,356 sling procedures were analysed, a UTI developed in 33.6 % of women within 3 months of surgery [44]. When considering obliterative surgery for advanced prolapse in older women, 45 % of women developed a UTI within 3 months of surgery [41]. This is a very high occurrence of a significant adverse event for many women; however, given the instrumentation of the urinary tract from catheters and cystoscopy inherent in many prolapse operations, it is understandable. In order to reduce postoperative UTI, targeted strategies are needed. Risk factors that can be modified need to be identified.

In a case-control study by Sutkin et al., the risk of UTI within 6 weeks of surgery for POP or SUI was 9.0 % [45•]. This compares to the SISTEr trial, mentioned above, where almost 17 % of women were treated for UTI within 6 weeks of surgery [46]. Two factors, which were found to increase the risk of UTI postsurgery, were transurethral catheterisation and incomplete bladder emptying [47]. These findings were in spite of the use of prophylactic antibiotics.

One of the bladder’s natural mechanical defences against UTIs is its ability to empty; however, this is compromised by the transient urinary retention that can occur commonly after pelvic floor surgery [48, 49]. There are a number of causes for postoperative retention including anaesthesia, swelling and oedema of tissues, denervation, devascularisation and opioid use. The subsequent placement of a catheter to empty the bladder, which is frequently left in situ, is well known to increase the risk of UTI [50]. In the SISTEr trial, catheterisation after a failed trial of void resulted in a more than two-fold increase in risk of UTI [46]. Another study found a more than four-fold increase in risk for postoperative UTI in women who failed a trial of void and subsequently had a catheter placed for more than 10 days [47].

When defining an acceptable trial of void, a commonly used range of PVR in clinical practice is 75–150 mL [45•]. For women with preoperative PVRs greater than 200 mL (and in some cases much higher), women with severe prolapse, and for those being discharged on the day of surgery, such a range may be inappropriate. With a trend towards day of surgery discharge, the shorter postoperative period may not provide sufficient time for the resolution of urinary retention. Indeed, there may be a rush for a clinical decision to be made about the need for catheterisation with a tendency to place a catheter if there is any doubt, in order to reduce the patient having to re-present to hospital after hours. This situation therefore presents a clinical challenge. In order to reduce postoperative UTI, a balance needs to be found between appropriate but not overzealous use of catheters. This should be tailored to the individual patient taking into account her age, mobility, type or surgical repair, presence of preoperative recurrent UTIs and preoperative PVRs [51••].

Paradoxically, Sutkin et al. reported that the risk of UTI was increased by a larger UAD (adjusted OR 1.4). The POP-Q examination, where the genital hiatus and the perineal body are measured, allowed the hypothesis that a decreased UAD would increase enteric colonisation of the bladder to be tested. At first thought it appears counterintuitive that increasing the distance between the exit and entry points of enteric organisms would increase the risk of UTI. However, the authors proposed that this increased UAD is a surrogate marker for global pelvic floor neurological and muscular compromise, which manifests itself as prolapse—descent of the perineum and pelvis [52]. As the neuromuscular compromise and pelvic floor dysfunction is unchanged after prolapse surgery, despite the fact that the UAD will decrease, the risk of urinary stasis and UTI development may remain in these women.

There are no studies that we could find in writing this review that tested the effect of prolapse treatment on reducing the risk of subsequent UTI. Whilst reducing and repairing prolapse may assist in reducing PVR, a well-established factor in the development of UTIs in these patients, the role of global pelvic floor dysfunction should not be discounted. Therefore, it is likely that surgical treatment of prolapse alone will be insufficient to prevent UTIs for many women. More research in this area is warranted.

Postoperative use of prophylactic antibiotics is controversial. Routine antibiotics to prevent UTI in women with asymptomatic bacteriuria associated with catheter use are not generally recommended [53, 54, 55, 56, 57••]. In a randomised trial of women with suprapubic catheters placed for incomplete emptying after prolapse surgery, nitrofurantoin prophylaxis was shown to decrease the rate of symptomatic UTIs [58].

Further research to explore urinary acidifiers and other non-antibiotic measures such as vaginal oestrogens and other nutriceuticals are required.

Conclusions

POP and UTI are both common problems, causing considerable morbidity for women. Whilst both problems occur frequently in isolation, there is a considerable cohort of women who suffer from both. Clinical examination and an ultrasound assessment of PVR should be performed in all women presenting with prolapse and UTI. Elevated PVR is the most significant risk factor, linking POP with UTI. The major risk factors for postoperative UTI are postoperative catheterisation and prolonged catheterisation, as well as previous history of recurrent UTI and increased UAD. There is a need for more evidence on the use of catheters to manage transient postoperative retention, as well as more research to find ways of preventing UTI in this group.

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Rizwan Hamid and Giovanni Losco declare they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Foxman B. Recurrent urinary tract infections: incidence and risk factors. Am J Public Health. 1990;80:331–3.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Stern JA, Hsieh YC, Schaeffer AJ. Residual urine in an elderly female population: novel implications for oral oestrogen replacement and impact on recurrent urinary infections. J Urol. 2004;171:768–70.PubMedCrossRefGoogle Scholar
  3. 3.
    O’Reilly M. Recurrent urinary tract infections. In: Stanton SL, Dwyer PL, editors. Urinary tract infection in the female. London: Martin Dunitz; 2000. p. 227–36.Google Scholar
  4. 4.
    Bruce AW, Reid G, McGroarty JA, Taylor M, Preston C. Preliminary study on the prevention of recurrent urinary tract infections in adult women using intravaginal lactobacilli. Int Urogynecol J. 1992;3:22–5.CrossRefGoogle Scholar
  5. 5.
    Franco AVM. Recurrent urinary tract infections. Best Pract Res Clin Obstet Gynaecol. 2005;19:861–73.PubMedCrossRefGoogle Scholar
  6. 6.
    Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta K. Risk factors for recurrent UTI in young women. Clin Infect Dis. 1997;25:440.Google Scholar
  7. 7.
    Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta K, Stamm WE. Risk factors for recurrent UTI in young women. J Infect Dis. 2000;182:1177–82.PubMedCrossRefGoogle Scholar
  8. 8.
    Foxman B, Manning SD, Tallman P, et al. Uropathogenic Escherichia coli are more likely than commensal E. coli to be shared between heterosexual sex partners. Am J Epidemiol. 2000;156:1133–40.CrossRefGoogle Scholar
  9. 9.
    Fihn SD, Boyko EJ, Normand EH, et al. Association between the use of spermicide-coated condoms and Escherichia coli urinary tract infection in young women. Am J Epidemiol. 1996;144:512–20.PubMedCrossRefGoogle Scholar
  10. 10.
    Hopkins WJ, Uehling DT, Wargowski DS. Evaluation of a familial disposition to recurrent urinary tract infections in women. Am J Med Genet. 1999;83:422–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Hooton TM, Stapleton AE, Roberts PL, et al. Perineal anatomy and urine voiding characteristics of young women with and without recurrent urinary tract infections. Clin Infect Dis. 1999;29:1600–1.PubMedCrossRefGoogle Scholar
  12. 12.
    Fowler JE, Latta R, Stamey TA. Studies of introital colonization in women with recurrent urinary tract infections: VIII. The role of bacterial interference. J Urol. 1975;113:214–7.Google Scholar
  13. 13.
    Stapleton A, Nudelman E, Clausen H, Hakomori S, Stamm WE. Binding of uropathogenic Escherichia coli R45 to glycolipids extracted from vaginal epithelial cells is dependent on histo-blood group secretor status. J Clin Invest. 1992;90:965–72.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Raz R, Stamm WE. A controlled trial of intravaginal oestriol in postmenopausal women with recurrent urinary tract infections. N Eng J Med. 1993;329:753–6.CrossRefGoogle Scholar
  15. 15.
    Raz R, Gennesin Y, Wasser J. Recurrent urinary tract infections in postmenopausal women. Clin Infect Dis. 2000;30:152–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Olsen AL, Smith VJ, Bergstrom JO, et al. Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol. 1997;89:501–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Hendrix SL, Clark A, Nygaard I, et al. Pelvic organ prolapse in the women’s health initiative: gravity and gravidity. Am J Obstet Gynecol. 2002;186:1160–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Boyles SH, Weber AM, Meyn L. Procedures for pelvic organ prolapse in the United States, 1979–1997. Am J Obstet Gynecol. 2003;188:108–15.PubMedCrossRefGoogle Scholar
  19. 19.••
    Morris R, Mock S, Dmochowski R. The case for robotics in pelvic prolapse surgery. Curr Bladder Dysfunct Rep. 2014;9:1–5. This review provides a good summary of the current techniques for treating prolapse. CrossRefGoogle Scholar
  20. 20.
    Herschorn S. Female pelvic floor anatomy: the pelvic floor, supporting structures, and pelvic organs. Rev Urol. 2004;6(suppl5):S2–10.PubMedCentralPubMedGoogle Scholar
  21. 21.
    Ashton-Miller JA, DeLancey JO. Functional anatomy of the female pelvic floor. Ann N Y Acad Sci. 2007;1101:266–96.PubMedCrossRefGoogle Scholar
  22. 22.
    Brubaker L, Bump RC, Fynes M. Surgery for pelvic organ prolapse. In: Abrams P, Cordozo L, Koury S, Wein A, editors. Third international consultation on incontinence. 1st ed. Paris: Health Publication; 2005.Google Scholar
  23. 23.•
    Linder BJ, Elliott DS. Robotic sacrocolpopexy: how does it compare with other prolapse repair techniques? Curr Urol Rep. 2013;14(3):235–9. This review addresses operative techniques, success rates, costs and complications among the various approached to sacrocolpopexy. PubMedCrossRefGoogle Scholar
  24. 24.
    Sobel JD, Kaye D. Urinary tract infections. In: Mandell Gl, Bennett JC, Dolin R, eds. Mandell, Douglas, and Bennett’s: principles and practice of infectious disease. 7th ed. Philadelphia, PA: Elsevier; 2010:957.Google Scholar
  25. 25.
    Nicolle LE. Urinary tract infection: traditional pharmacologic therapies. Am J Med. 2002;113(suppl 1A):35S–44.PubMedCrossRefGoogle Scholar
  26. 26.
    Monane M, Gurwitz JH, Lipsitz LA, Glynn RJ, Choodnovskiy I, Avorn J. Epidemiologic and diagnostic aspects of bacteriuria: a longitudinal study in older women. J Am Geriatr Soc. 1995;43:618–22.PubMedGoogle Scholar
  27. 27.
    Kaye D, Boscia JA, Abrutyn E, Levison ME. Asymptomatic bacteriuria in the elderly. Trans Am Clin Climatol Assoc. 1989;100:155–62.PubMedCentralPubMedGoogle Scholar
  28. 28.
    Nicolle LE. Urinary tract infections in the elderly. Clin Geriatr Med. 2009;25:423–36.PubMedCrossRefGoogle Scholar
  29. 29.••
    Mody L, Juthani-Mehta M. Urinary tract infections in older women: a clinical review. JAMA. 2014;311:844–54. This excellent review gives a clinical approach to the diagnosis and management of UTI in the elderly female. PubMedCrossRefGoogle Scholar
  30. 30.
    Matthews SJ, Lancaster JW. Urinary tract infections in the elderly population. Am J Geriatr Pharmacother. 2011;9:286–309.PubMedCrossRefGoogle Scholar
  31. 31.
    Epp A, Larochelle A, Lovatsis D, Society of Obstetricians and Gynaecologists of Canada, et al. Recurrent urinary tract infection. J Obstet Gynaecol Can. 2010;32:1082–101.PubMedGoogle Scholar
  32. 32.
    Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005;40:643–54.PubMedCrossRefGoogle Scholar
  33. 33.
    Mazzulli T. Diagnosis and management of simple and complicated urinary tract infections (UTIs). Can J Urol. 2012;19(suppl1):42–8.PubMedGoogle Scholar
  34. 34.
    Haylen B, Lee J, Husselbee S, Law M, Zhou J. Recurrent urinary tract infections in women with symptoms of pelvic floor dysfunction. Int Urogynecol J. 2009;20:837–42.CrossRefGoogle Scholar
  35. 35.
    O’Grady F, Cattell WR. Kinetics of urinary tract infections II. The bladder Br J Urol. 1996;38:156–62.CrossRefGoogle Scholar
  36. 36.
    Haylen BT, Lee J, Logan V, Husselbee S, Zhou J, Law M. Immediate postvoid residual volumes in women with symptoms of pelvic floor dysfunction. Obstet Gynecol. 2008;111:1305–12.PubMedCrossRefGoogle Scholar
  37. 37.
    Haylen BT, Law MG, Frazer M, Schulz S. Urine flow rates and residual urine volumes in urogynaecology patients. Int Urogynecol J. 1999;10:378–83.CrossRefGoogle Scholar
  38. 38.
    Haylen BT, Verity L, Schulz S, Zhou J, Krishnan S, Sutherst JR. Has the true incidence of voiding difficulty in women been underestimated? Int Urogynecol J. 2007;18:53–6.CrossRefGoogle Scholar
  39. 39.
    Novi JM, Jeronis S, Morgan MA, Arya LA. Sexual function in women with pelvic organ prolapse compared to women without pelvic organ prolapse. J Urol. 2005;173:1669–72.PubMedCrossRefGoogle Scholar
  40. 40.
    Albo ME, Richter HE, Brubaker L, et al. Burch colposuspension versus fascial sling to reduce urinary stress incontinence. N Engl J Med. 2007;356:2143–55.PubMedCrossRefGoogle Scholar
  41. 41.
    FitzGerald MP, Richter HE, Bradley CS, et al. Pelvic support, pelvic symptoms, and patient satisfaction after colpocleisis. Int Urogynecol J. 2008;19:1603–9.CrossRefGoogle Scholar
  42. 42.
    Bump RC, Norton PA. Epidemiology and natural history of pelvic floor dysfunction. Obstet Gynecol Clin North Am. 1998;25:723–46.PubMedCrossRefGoogle Scholar
  43. 43.
    Olsen AL, Smith VJ, Bergstrom JO, Colling JC, Clark AL. Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol. 1997;89:501–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Anger JT, Litwin MS, Wang Q, Pashos CL, Rodriguez LV. Complications of sling surgery among female medicare beneficiaries. Obstet Gynecol. 2007;109:707–14.PubMedCrossRefGoogle Scholar
  45. 45.•
    Sutkin G, Alperin M, Meyn L, Wiesenfeld HC, Ellison R, Zyczynski HM. Symptomatic urinary tract infections after surgery for prolapse and/or incontinence. Int Urogynecol J. 2010;21:955–61. This interesting case-control study examination risk factors for UTI in women undergoing POP or SUI surgery. PubMedCrossRefGoogle Scholar
  46. 46.
    Chai TC, Albo ME, Richter HE, Norton P, Dandreo KJ, et al. Analysis of adverse events from the stress incontinence surgical treatment efficacy trial (SISTEr). J Pelvic Med Surg. 2007;13:259.Google Scholar
  47. 47.
    Kringel U, Reimer T, Tomczak S, Green S, Kundt G, Gerber B. Postoperative infections due to bladder catheters after anterior colporrhaphy: a prospective, randomized, three-arm study. Int Urogynecol J. 2010;21:1499–504.PubMedCrossRefGoogle Scholar
  48. 48.
    Mutone N, Brizendine E, Hale D. Factors that influence voiding function after the tension-free vaginal tape procedure for stress urinary incontinence. Am J Obstet Gynecol. 2003;188:1477–83.PubMedCrossRefGoogle Scholar
  49. 49.
    Cox CE, Hinman F. Experiments with induced bacteriuria, vesicle emptying and bacterial growth on the mechanism of bladder defenses to infection. J Urol. 1961;83:739.Google Scholar
  50. 50.
    Foxman B, Brown P. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin N Am. 2003;17:227–41.CrossRefGoogle Scholar
  51. 51.••
    Baessler K, Maher C. Pelvic organ prolapse surgery and bladder function. Int Urogynecol J. 2013;24:1843–52. This paper provides a good summary of guidance on when to treat bladder disorders at the time of prolapse surgery, including guidance on the use of prophylactic antibiotics. PubMedCrossRefGoogle Scholar
  52. 52.
    DeLancey JO, Hurd WW. Size of the urogenital hiatus in the levator ani muscles in normal women and women with pelvic organ prolapse. Obstet Gynecol. 1998;91:364–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Trautner BW, Darouiche RO. Catheter-associated infections. Arch Intern Med. 2004;164:842–50.PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.
    Saint S, Chenowith CE. Biofilms and catheter-associated urinary tract infections. Infect Dis Clin N Am. 2003;17:411–32.CrossRefGoogle Scholar
  55. 55.
    Wyndeale JJ. Complications of intermittent catheterization: their prevention and treatment. Spinal Cord. 2002;40:536–41.CrossRefGoogle Scholar
  56. 56.
    Galloway A, Green HT, Windsor JJ, Menon KK, Gardner BP, Krishnan KR. Serial concentrations of C-reactive protein as an indicator of urinary tract infection in patients with spinal injury. J Clin Pathol. 1986;39:851–5.PubMedCentralPubMedCrossRefGoogle Scholar
  57. 57.••
    De Tayrac R, Sentilhes L. Complications of pelvic organ surgery and methods of prevention. Int Urogynecol J. 2013;24:1859–72. This useful paper summaries many of the complications associated with prolapse surgery at the current time and provides grades of recommendation for their prevention. PubMedCrossRefGoogle Scholar
  58. 58.
    Rogers RG, Kammer-Doak D, Olsen A, et al. A randomized, double-blind, placebo-controlled comparison of the effect of nitrofurantoin monohydrate macrocrystals on the development of urinary tract infections after surgery for pelvic organ prolapse and/or stress urinary incontinence with suprapubic catheterization. Am J Obstet Gynecol. 2004;191:182–7.PubMedCrossRefGoogle Scholar

Copyright information

© The Author(s) 2014

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

Authors and Affiliations

  1. 1.Department of NeurourologyRoyal National Orthopaedic HospitalStanmoreUK
  2. 2.Department of UrologyUniversity College HospitalLondonUK

Personalised recommendations